<DOC>
	<DOCNO>NCT02263248</DOCNO>
	<brief_summary>The Investigators conduct research study learn safety benefit use medication call buprenorphine patient difficult treat depression . This research study test whether combine two medication effective treat depression initial treatment one antidepressant relieve depressive symptom ; call `` difficult treat depression `` `` treatment resistant depression `` . The two medication investigator use `` anti-depressant medication call venlafaxine XR ( generic form Effexor ) buprenorphine . Buprenorphine medication FDA approve treatment opioid dependence . The investigator test whether add buprenorphine venlafaxine enhances treatment response .</brief_summary>
	<brief_title>Incomplete Response Late-Life Depression : Getting Remission With Buprenorphine</brief_title>
	<detailed_description>The aim study examine feasibility , safety , tolerability buprenorphine ( BPN ) novel treatment late-life treatment resistant depression ( LL-TRD ) . The investigator aim use clinical trial methodology common three site , examine mechanism action ( MOA ) BPN use translational neuroscience method . Over Â½ senior depression fail respond traditional antidepressants.19,20 Modulation opiate system BPN offer novel mechanistic approach improve live patient LL-TRD , safety profile potentially superior current augmentation strategy antipsychotic , lithium , ECT , surgical intervention ( e.g. , deep brain vagal nerve stimulation ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Age &gt; 50 year 2 . Major depressive disorder ( MDD ) , single recurrent , diagnose SCIDIV ( SCID5 available ) 3 . MADRS &gt; 15 4 . Has agree establish clinical relationship primary care physician ( PCP ) . 5 . Availability informant ( e.g. , emergency contact ) encourage require study participation 1 . Inability provide inform consent 2 . Depressive symptom severe enough ( i.e. , MADRS &lt; 15 ) baseline assessment 3 . Dementia , define 3MS &lt; 80 clinical evidence dementia 4 . Lifetime diagnosis bipolar I II disorder , schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , current psychotic symptom , diagnose SCID 5 . Abuse dependence alcohol substance within past 3 month determine SCID , score &gt; 8 AUDITC confirm study physician interview 6 . High risk suicide ( e.g. , active SI and/or current/recent intent plan ) AND unable manage safely clinical trial ( e.g. , unwilling hospitalize ) . Urgent psychiatric referral make case 7 . Contraindication venlafaxine buprenorphine determine PCP study physician include history intolerance either venlafaxine buprenorphine study target dosage range ( venlafaxine 300 mg/day ; buprenorphine 1.2 mg/day ) 8 . Inability communicate English ( i.e. , interview conduct without interpreter ; subject largely unable understand question respond English ) 9 . Noncorrectable clinically significant sensory impairment ( i.e. , hear well enough cooperate interview ) 10 . Unstable medical illness , include delirium , uncontrolled diabetes mellitus , hypertension , hyperlipidemia , cerebrovascular cardiovascular risk factor medical management . This determine base information patient 's personal physician study physician 's clinical judgment . Referral patient 's personal physician general practitioner make case 11 . Subjects take psychotropic medication safely taper discontinue prior study initiation . The following exception allow take stable dose least 4 week prior study entry plan change dose next 32 36 week : benzodiazepine 2 mg/d lorazepam equivalent ; sedativehypnotics ( e.g. , zolpidem , zaleplon , eszopiclone ) ; gabapentin prescribed nonpsychiatric indication ( e.g. , neuropathy ) 12 . History opiate abuse dependence 13 . Severe pain , define &gt; 7 010 numeric rating scale pain 14 . Concomitant use strong moderate CYP3A4 inhibitor ( indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketonazole , nefazodone , saquinovir , telithromycin , aprepitant , erythromycin , fluconazole , grapefruit juice , verapamil , diltiazem ) 15 . Refusal stop opioids ( avoid precipitate opioid withdrawal ) 16 . Refusal discontinue alcohol ( reduce risk respiratory depression ) 17 . Hepatic impairment ( AST/ALT &gt; 1.5 time upper normal ) 18 . Estimated Glomerular Filtration Rate ( GFR ) &lt; 20 ml/min 19 . Inability/refusal identify person emergency contact</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>